This report was first published by Endpoints News. To see the original version, click here
The global race to develop in vivo CAR-T therapies that could replace onerous cell therapies with simpler, safer infusions continues to heat up, and now a Chinese biotech startup has quietly begun clinical tests of its treatments.
In an exclusive interview with Endpoints News, Starna Therapeutics said it’s seen complete elimination of circulating B cells — the cells that can run amok in autoimmune disease and blood cancer — following a single infusion of its treatment in a small, undisclosed number of lupus patients and a single non-Hodgkin lymphoma patient.
您已閱讀11%（653字），剩余89%（5372字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。